Bicara Therapeutics Inc. (BCAX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $20.03: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor... Read more
Sell if holding. Engine safety override at $20.03: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: aggressive.
Recent Developments — Bicara Therapeutics Inc.
Latest news
- Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $18 — benzinga May 12, 2026 positive
- Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $37 — benzinga May 12, 2026 positive
- Guggenheim Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $42 — benzinga May 11, 2026 positive
- Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate — benzinga May 11, 2026 negative
- Earnings Scheduled For May 11, 2026 — benzinga May 11, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.03: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $18.63. Score 5.2/10, moderate confidence.
Take-profit target: $27.37 (+36.6% upside). Prior stop was $18.63. Stop-loss: $18.63.
Quality below floor (1.6 < 4.0).
Bicara Therapeutics Inc. trades at a P/E of N/A (forward -5.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover BCAX with a consensus score of 4.1/5. Average price target: $31.
What does Bicara Therapeutics Inc. do?Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional...
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.